Please use this identifier to cite or link to this item: http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/4759
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIlkaya, F.-
dc.contributor.authorYuce, M.-
dc.contributor.authorAgri, A. E.-
dc.contributor.authorGuzel, H.-
dc.contributor.authorBalci, H.-
dc.contributor.authorUcar, F.-
dc.contributor.authorBabadagi, Z.-
dc.contributor.authorMujdeci, M.-
dc.contributor.authorMutlu, E.-
dc.date.accessioned2024-03-19T06:56:04Z-
dc.date.available2024-03-19T06:56:04Z-
dc.date.issued2015-
dc.identifier.citationIlkaya, F., Yüce, M., Agri, AE., Güzel, H., Balci, H., Uçar, F., Babadagi, Z., Müjdeci, M., Mutlu, E. (2015). The combination of agomelatine and ritanserin exerts a synergistic interaction in passive avoidance task. Hum. Exp. Toxicol., 34(8), 787-795. https://doi.org/10.1177/0960327114559613en_US
dc.identifier.issn0960-3271-
dc.identifier.issn1477-0903-
dc.identifier.urihttp://dx.doi.org/10.1177/0960327114559613-
dc.identifier.urihttps://www.webofscience.com/wos/woscc/full-record/WOS:000358578400001-
dc.identifier.urihttp://earsiv.odu.edu.tr:8080/xmlui/handle/11489/4759-
dc.descriptionWoS Categories: Toxicologyen_US
dc.descriptionWeb of Science Index: Science Citation Index Expanded (SCI-EXPANDED)en_US
dc.descriptionResearch Areas: Toxicologyen_US
dc.description.abstractAgomelatine is a potent agonist at melatonergic 1 and 2 (MT1 and MT2) receptors and an antagonist at serotonin-2C (5HT-2C) receptors. It was suggested that psychotropic effects of agomelatine is associated with its melatonergic and serotonergic effects. In this study, we aimed to evaluate the effects of agomelatine alone or in combination with ritanserin (5HT-2A/2C antagonist) on memory and learning. Male Balb-C mice (25-30 g) were used, and all drugs and saline were administrated by intraperitoneal (i.p.) route 30 min prior to evaluating retention time. Whilst agomelatine was administered at the doses of 1, 10 and 30 mg/kg, ritanserin was administered at the doses of 0.1, 1 and 10 mg/kg. To evaluate memory function, passive avoidance test was used. On the first day, acquisition time and on the second day (after 24h), retention time of mice were recorded. To evaluate the synergistic activity, only the least doses of agomelatine and ritanserine were used, that is, 1 and 0.1 mg/kg, respectively. Scopolamine (1 mg/kg) was used as a reference drug, so it was combined with drug groups. Our results show that 5HT-2A/2C receptor antagonist ritanserin (1 and 4 mg/kg, i.p.) and agomelatine (10 and 30 mg/kg, i.p.) improve memory deficit induced by scopolamine, whilst a synergistic interaction is observed between ritanserin and agomelatine (0.1 mg/kg and 1 mg/kg, i.p., respectively) when they were administered at their ineffective doses. According to our findings, we concluded that agomelatine improves memory deficit and thus improves the effect of agomelatine arises from its 5HT-2C receptor antagonist activity.en_US
dc.language.isoengen_US
dc.publisherSAGE PUBLICATIONS LTD-LONDONen_US
dc.relation.isversionof10.1177/0960327114559613en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAgomelatine, ritanserin, serotonin 2 receptors, passive avoidance, synergismen_US
dc.subjectELEVATED PLUS-MAZE, ALZHEIMERS-DISEASE, ANTIDEPRESSANT AGOMELATINE, COGNITIVE PERFORMANCE, MELATONIN RECEPTORS, 5-HT2C RECEPTORS, INDUCED AMNESIA, MOOD DISORDERS, BINDING-SITES, MT2 RECEPTORSen_US
dc.titleThe combination of agomelatine and ritanserin exerts a synergistic interaction in passive avoidance tasken_US
dc.typearticleen_US
dc.relation.journalHUMAN & EXPERIMENTAL TOXICOLOGYen_US
dc.contributor.departmentOrdu Üniversitesien_US
dc.contributor.authorID0000-0003-4106-3211en_US
dc.identifier.volume34en_US
dc.identifier.issue8en_US
dc.identifier.startpage787en_US
dc.identifier.endpage795en_US
Appears in Collections:Dahili Tıp Bilimleri

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.